Curated News
By: NewsRamp Editorial Staff
October 30, 2026
CCHR Exposes ADHD Assessment Risks After US, Sweden Legal Actions
TLDR
- CCHR's report exposes ADHD diagnostic fraud, giving parents and advocates leverage to demand accountability and push for stricter oversight of stimulant prescriptions.
- CCHR details legal actions in the US and Sweden where courts convicted or shut down ADHD assessment schemes lacking objective tests, relying on subjective checklists.
- CCHR's efforts aim to protect vulnerable children and adults from unproven ADHD diagnoses and risky stimulants, fostering a safer, more ethical mental health system.
- A Swedish ADHD clinic promised refunds if no diagnosis, yet refunded only 1 in 500, earning $5.5 million before being banned for patient safety risks.
Impact - Why it Matters
The legal actions and CCHR's warnings underscore a critical issue: millions of children and adults are being diagnosed with ADHD based on subjective checklists and placed on powerful, addictive stimulants without any objective medical test. This news matters because it reveals how profit-driven practices can compromise patient safety, leading to addiction, psychosis, and even death. Parents and patients must understand that an ADHD diagnosis is not a confirmed biological disease, and they should question assessments that lack scientific rigor. The convictions and closures also signal that regulators and law enforcement are beginning to hold accountable those who exploit the system. As stimulant prescriptions continue to rise, this case serves as a wake-up call for greater oversight and informed consent in mental health care.
Summary
The Citizens Commission on Human Rights International (CCHR) is calling for greater accountability in ADHD assessments and diagnoses following a series of legal actions in the United States and Sweden that exposed questionable practices in the booming ADHD industry. In Sweden, the Health and Social Care Inspectorate banned an online ADHD diagnostic company after finding a "clear and serious risk to patients' health, safety and lives." The company offered a "diagnosis or your money back" guarantee—but only refunded patients who did not receive an ADHD diagnosis, which occurred in just 1 out of 500 cases. The company generated roughly $5.5 million in revenue in 2024 before being shut down. In the U.S., a federal jury convicted a physician in October 2026 of conspiracy and multiple counts of illegally distributing controlled substances through an ADHD telehealth platform, where more than two million stimulant pills were prescribed without examining patients. This case is part of a larger federal prosecution involving 37 million ADHD stimulant pills and a $100 million health care fraud scheme.
CCHR argues these cases highlight the dangers of subjective ADHD diagnoses and aggressive stimulant promotion. The group points out that ADHD has no objective medical test—no blood work, scan, or biomarker—and diagnosis relies entirely on reported behaviors that are often indistinguishable from normal human tendencies. CCHR cites a 2025 warning from The Journal of the Royal Society of Medicine about an "epidemic of ADHD diagnosing and prescribing" fueled by self-administered checklists. The organization also emphasizes documented risks of ADHD stimulants, including addiction, psychosis, and other serious side effects. Jan Eastgate, President of CCHR International, stated: "The entire ADHD diagnostic and drug industry needs an overhaul. Any diagnosis that cannot be medically and scientifically proven should be dismissed."
CCHR, a mental health industry watchdog established in 1969 by the Church of Scientology and professor of psychiatry Dr. Thomas Szasz, has helped enact hundreds of laws worldwide to protect the public from abusive practices. The group is urging parents and patients to be aware that online and other ADHD assessments lack objective scientific foundation and are often driven by checklists of ordinary behaviors rather than confirmed disease. With stimulant prescriptions skyrocketing—over 3 million children and adolescents were taking ADHD drugs in 2020—CCHR insists that far greater accountability is needed for diagnostic practices that function more like sales pipelines than medical evaluations.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, CCHR Exposes ADHD Assessment Risks After US, Sweden Legal Actions
